



RECEIVED
TECH
APR 25 2002
1600/2900

PTO/SB/08B(10-01)
Approved for use through 10/31/2002. OMB 0657-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	09/990,119
Filing Date	November 21, 2001
First Named Inventor	Sabine Brüsselbach
Group Art Unit	1615
Examiner Name	
Attorney Docket Number	BPD-101XC1

Sheet 3 of 5

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R14	HAROKOPAKIS, EVLAMBIA, NOEL K. CHILDERS, SUZANNE M. MICHALEK, SHUHUA S. ZHANG, and MAURIZIO TOMASI, "Conjugation of Cholera Toxin or its B Subunit to Liposomes for Targeted Delivery of Antigens", <i>Journal of Immunological Methods</i> , 1995, pages 31-42, Vol. 185.	
	R15	HENZE A., J. FREISE, P. MAGERSTEDT, and A. MAJEWSKI, "Radio-opaque Liposomes for the Improved Visualization of Focal Liver Disease by Computerized Tomography. <i>Comput Med Imaging Graph</i> , November-December 1989, pages 455-462, Vol. 13. No. 6.	
	R16	HUDSON, PETER J., "Recombinant Antibody Fragments", <i>Current Opinion in Biotechnology</i> , 1998, pages 395-402, Vol. 9.	
	R17	JAIN, RAKESH K., "Delivery of Molecular and Cellular Medicine to Solid Tumors", <i>Journal of Controlled Release</i> , 1998, pages 49-67, Vol. 53.	
	R18	KANDA, TERU, KEVIN F. SULLIVAN, and GEOFFREY M. WAHL, "Histone-GFP Fusion Protein Enables Sensitive Analysis of Chromosome Dynamics in Living Mammalian Cells", <i>Current Biology</i> , 1998, pages 377-385, Vol. 8.	
	R19	KANDARAKIS, I., D. CAVOURAS, G. S. PANAYIOTAKIS, D. TRIANTIS, C. D. NOMICOS, "Europium-activated Phosphors for Use in X-ray Detectors of Medical Imaging Systems", <i>Eur. Radiol.</i> , 1998, pages 313-318, Vol. 8.	
	R20	KIKUCHI, A., S. SUGAYA, H. UEDA, K. TANAKA, Y. ARAMAKI, T. HARA, H. ARIMA, S. TSUCHIYA, and T. FUWA, "Efficient Gene Transfer of EGF Receptor Overexpressing Cancer Cells by Means of EGF-labeled Cationic Liposomes", <i>Biochemical and Biophysical Research Communications</i> , 1996, pages 666-671, Vol. 227.	
	R21	KOIVUNEN, ERKKI, BINGCHENG WANG, and ERKKI RUOSLAHTI, "Phage Libraries Displaying Cyclic Peptides with Different Ring Sizes: Ligand Specificities of the RGD-Directed Integrins", <i>BioTechnology</i> , March 1995, pages 265-270, Vol. 13.	
	R22	LEE, ROBERT J. and PHILIP S. LOW, "Delivery of Liposomes into Cultured KB Cells via Folate Receptor-mediated Endocytosis", <i>The Journal of Biological Chemistry</i> , February 4, 1994, pages 3198-3204, Vol. 269, No. 5.	
	R23	MACDONALD, ROBERT C., RUBY, J. MACDONALD, BERT PH. M. MENCO, KEIZO TAKESHITA, NANDA K. SUBBARAO, and LAN-RONG HU, "Small-volume Extrusion Apparatus for Preparation of Large, Unilamellar Vesicles", <i>Biochimica et Biophysica Acta</i> , 1991, pages 297-303, Vol. 1061.	
	R24	MARTIN, FRANCIS J. and DEMETRIOS PAPAHAADJOPOULOS, "Irreversible Coupling of Immunoglobulin Fragments to Preformed Vesicles", <i>The Journal of Biological Chemistry</i> , January 10, 1982, pages 286-288, Vol. 257, No. 1.	
	R25	MARUYAMA, K., T. YUDA, A. OKAMOTO, S. KOJIMA, A. SUGINAKA, and M. IWATSURU, "Prolonged Circulation Time <i>In Vivo</i> of Large Unilamellar Liposomes Composed of Distearoyl Phosphatidylcholine and Cholesterol Containing Amphipathic Poly(ethylene glycol)", <i>Biochim Biophys Acta</i> , 1992, pages 44-49, Vol. 1128.	
	R26	MARUYAMA, K., O. ISHIDA, T. TAKIZAWA, K. MORIBE <i>Adv. Drug Del. Rev.</i> , 1999, pages 89-102, Vol. 40.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



TECH 1600/2900

APR 25 2002

RECEIVED

PTO/SB/088 (10-99)

Approved for use through 10/31/2002. OMB 0651-0023
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Patent and Trademark Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	09/990,119
Filing Date	November 21, 2001
First Named Inventor	Sabine Brüsselbach
Group Art Unit	1615
Examiner Name	
Attorney Docket Number	BPD-101XC1

Sheet 4 of 5

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R27	MILLER, D. W., W. GRAULICH, B. KARGES, S. STAHL, M. ERNST, A. RAMASWAMY, H. SEDLACEK, R. MÜLLER, and J. ADAMKIEWICZ, "Elevated Expression of Endoglin, a Component of the TGF- β -Receptor Complex, Correlates with Proliferation of Tumor Endothelial Cells" <i>Int. J. Cancer</i> , 1999, pages 568-572, Vol. 81.	
	R28	PASQUALINI, RENATA, ERKKI KOIVUNEN, and ERKKI RUOSLAHTI, "av Integrins as Receptors for Tumor Targeting by Circulating Ligands", <i>Nature Biotechnology</i> , June 1997, pages 542-546, Vol. 15.	
	R29	PASQUALINI, R., E. KOIVUNEN, R. KAIN, J. LAHDENRANTA, M. SAKAMOTO, A. STRYHN, R. A. ASHMUN, L. H. SHAPIRO, W. ARAP, and E. RUOSLAHTI, "Aminopeptidase N is a Receptor for Tumor-homing Peptides and a Target for Inhibiting Angiogenesis", <i>Cancer Research</i> , February 1, 2000, pages 722-727, Vol. 60.	
	R30	PIERSCHBACHER, MICHAEL D. and ERKKI RUOSLAHTI, "Cell Attachment Activity of Fibronectin can be Duplicated by Small Synthetic Fragments of the Molecule", <i>Nature</i> , May 3, 1984, pages 30-33, Vol. 309.	
	R31	PLATE, K. H., G. BREIER, H. A. WEICH, H. D. MENNEL, and W. RISAU, "Vascular Endothelial Growth Factor and Glioma Angiogenesis: Coordinate Induction of VEGF Receptors, Distribution of VEGF Protein and Possible <i>In Vivo</i> Regulatory Mechanisms", <i>Int. J. Cancer</i> , 1994, pages 520-529, Vol. 59.	
	R32	RUF, HORST, YANNIS GEORGALIS, and ERNST GRELL, "Dynamic Laser Light Scattering to Determine Size Distributions of Vesicles", <i>Methods in Enzymology</i> , 1989, pages 364-390, Vol. 172.	
	R33	RUOSLAHTI, E., "Fibronectin and Its Integrin Receptors in Cancer", <i>Adv. Cancer Res.</i> , 1999, pages 1-20, Vol. 76.	
	R34	SELTZER, STEVEN E., ANDREW S. JANOFF, MONTE BLAU, DOUGLASS F. ADAMS, SHARMA R. MINCHEY, and LAWRENCE T. BONI, "Biodistribution and Imaging Characteristics of Iotrolan-Carrying Interdigitation-Fusion Vesicles", <i>Invest. Radiol.</i> , 1991, pages S169-S171, Vol. 26.	
	R35	THORNTON, SUSAN C., STEPHEN N. MUELLER, and ELLIOT M. LEVINE, "Human Endothelial Cells: Use of Heparin in Cloning and Long-Term Serial Cultivation", <i>Science</i> , November 11, 1983, pages 623-625, Vol. 222, Issue 4624.	
	R36	THURSTON, G., J. W. MCLEAN, M. RIZEN, P. BALUK, A. HASKELL, T. J. MURPHY, D. HANAHAN, and D. M. MCDONALD, "Cationic Liposomes Target Angiogenic Endothelial Cells in Tumors and Chronic Inflammation in Mice", <i>J. Clin. Invest.</i> , April 1998, pages 1401-1413, Vol. 101, No. 7.	
	R37	URDAL, DAVID L., and SEN-ITIROH HAKOMORI, "Tumor-associated Ganglio-N-triosylceramide", <i>The Journal of Biological Chemistry</i> , November 10, 1980, pages 10509-10516, Vol. 255, No. 21.	
	R38	VERTUT-DOI, A., H. ISHIWATA, and K. MIYAJIMA, "Binding and Uptake of Liposomes Containing a Poly(ethylene glycol) Derivative of Cholesterol (Stealth Liposomes) by the Macrophage Cell Line J774: Influence of PEG Content and Its Molecular Weight", <i>Biochimica et Biophysica Acta</i> , 1996, pages 19-28, Vol. 1278.	
	R39	WAGNER, ERNST, DAVID CUIEL, MATTEN COTTEN, <i>Adv. Drug Del. Rev.</i> , 1994, pages 113-136, Vol. 14.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

+

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



TECH CENTER 600/2900

APR 25 2002

RECEIVED

PTO/SB/08B (10-99)

Approved for use through 10/31/2002. OMB 0651-0037

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	09/990,119
Filing Date	November 21, 2001
First Named Inventor	Sabine Brüsselbach
Group Art Unit	1615
Examiner Name	
Attorney Docket Number	BPD-101XC1

Sheet 5 of 5

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R40	WEISSIG, V., J. LASCH, A. L. KLIBANOV, and V. P. TORHILIN, "A New Hydrophobic Anchor for the Attachment of Proteins to Liposomal Membranes", <i>FEBS Letters</i> , June 1986, pages 86-90, Vol. 202, No. 1.	
	R41	WOODLE, M. C., C. M. ENGBERS, S. ZALIPSKY, "New Amphipatic Polymer-Lipid Conjugates Forming Long-Circulating Reticuloendothelial System-Evading Liposomes", <i>Bioconjugate Chem.</i> , November-December 1994, pages 493-496, Vol. 5, No. 6.	
	R42	WOODLE, M. C., K. K. MATTHAY, M. S. NEWMAN, J. E. HIDAYAT, L. R. COLLINS, C. REDEMANN, F. J. MARTIN, and D. PAPAHAADJOPOULOS, "Versatility in Lipid Compositions Showing Prolonged Circulation with Sterically Stabilized Liposomes", <i>Biochimica et Biophysica Acta</i> , 1992, pages 193-200, Vol. 1105.	
	R43	YUDA, TSUTOMU, KAZUO MARUYAMA, and MOTOHARU IWATSURU, "Prolongation of Liposome Circulation Time by Various Derivatives of Polyethyleneglycols", <i>Biol. Pharm. Bull.</i> , October 1996, pages 1347-1351, Vol. 19, No. 10.	
	R44	ZALIPSKY, SAMUEL, NASREEN MULLAH, JENNIFER A. HARDING, JOSHUA GITTELMAN, LUKE GUO, and SHAWN A. DEFREES, "Poly(ethylene glycol)-Grafted Liposomes with Oligopeptide or Oligosaccharide Ligands Appended to the Termini of the Polymer Chains", <i>Bioconjugate Chem.</i> , 1997, pages 111-118, Vol. 8.	
	R45		
	R46		
	R47		
	R48		
	R49		
	R50		
	R51		
	R52		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.